External Validation of the Assessment of Different NEoplasias in the adneXa Model Performance in Evaluating the Risk of Ovarian Carcinoma Before Surgery in China
External Validation of the Assessment of Different NEoplasias in the adneXa Model Performance in Evaluating the Risk of Ovarian Carcinoma Before Surgery in China
复制标题
adneXa 模型在评估中国术前卵巢癌风险方面的表现对不同肿瘤的评估的外部验证
DOI：
10.1002/jum.15920
复制
发表时间：
2021
期刊：
影响因子：
--
通讯作者：
li feng
中科院分区：
文献类型：
--
作者：
yixin zhang;yuli zhao;li feng
目的国际卵巢肿瘤分析组织（International Ovarian Tumor Analysis group）开发了ADNEX模型中不同肿瘤的评估，以评估卵巢肿块为恶性肿瘤的风险。本研究旨在外部验证ADNEX模型在中国某第三产业中心的有效性。方法采用回顾性、单中心的大学医院研究，评估模型的诊断准确性。所有患者均行阴道超声检查，测定血清CA125水平。并收集临床病理资料。以CA125为预测因子，计算ADNEX模型的诊断性能。结果我们检索了335例患者，其中53例根据排除标准被排除。282例患者中，良性肿瘤178例（63.1%），恶性肿瘤104例（36.9%）。当考虑CA125因素时，区分良恶性肿瘤的受者工作特征曲线下面积（AUC）为0.93(95%可信区间[CI]， 0.90-0.96)，而未考虑CA125的受者工作特征曲线下面积为0.91 （95% CI, 0.88-0.95）。校正图很好地证明了恶性肿瘤预测风险与观察到的恶性肿瘤比例之间的一致性。结论ADNEX模型的性能在国内三级中心得到了外部验证，显示出对肿瘤亚型的良好区分。我们的研究结果表明，ADNEX模型在临床实践中是一种有价值的工具，可能有助于管理患有附件肿块的患者。
ObjectivesThe Assessment of Different NEoplasias in the adneXa (ADNEX) model was developed by the International Ovarian Tumor Analysis group to assess the risk of an ovarian mass being malignant. This study aimed to externally validate the ADNEX model performance in a tertiary center in China.MethodsThis retrospective, single‐center university hospital study assessed the model diagnostic accuracy. All patients were examined by transvaginal ultrasonography, and serum CA125 levels were measured. Moreover, clinicopathological information was collected. The diagnostic performance of the ADNEX model was calculated with and without CA125 as a predictor.ResultsWe retrieved data of 335 patients, of which 53 were excluded based on the exclusion criteria. Of the included 282 patients, 178 (63.1%) had benign tumors, and 104 (36.9%) had malignant tumors. When CA125 was factored in, the area under the receiver operating characteristic curve (AUC) for the distinction between benign and malignant tumors was 0.93 (95% confidence interval [CI], 0.90–0.96), whereas it was 0.91 (95% CI, 0.88–0.95) without CA125. The concordance between the predicted risk of malignancy and the proportion of observed malignancies was well demonstrated by the calibration plots.ConclusionsThe proper performance of the ADNEX model was verified externally in a tertiary center in China, showing a good distinction between tumour subtypes. Our findings suggest the ADNEX model is a valuable tool in clinical practice and may help in managing patients with adnexal masses.